POSA246 A Real World Evaluation to Describe Resource Use for the Management of Moderate to Severe Atopic Dermatitis in Secondary Care for Children and Adolescents Aged 6 to 17 in the Republic of Ireland

Irvine, AD; Surendranathan, Thishi; Hennessy, Liz; Rajkovic, Ivana; Durkin, Anne; Collins, Tara Coughlan, Des O'Neill, Ronan; Hudson, R. M.

doi:10.1016/j.jval.2021.11.761

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A UK retrospective noninterventional study reported the considerable burden of hospital visits and complex treatment pathways in adults with moderate‐to‐severe AD, and suggested a lack of an effective long‐term treatment 10 . An equivalent Irish pediatric study supported these findings 11 . The present study aimed to describe secondary care health care resource utilization (HCRU), patient demographics, and patient‐reported outcome data for children and adolescents with moderate‐to‐severe AD in the UK.…”

Section: Introductionmentioning

confidence: 88%

See 1 more Smart Citation

A real‐world retrospective observational study exploring NHS resource use in England for the management of moderate‐to‐severe atopic dermatitis in secondary care for children and adolescents

McPherson

Cork

Goodhead

et al. 2022

Pediatric Dermatology

View full text Add to dashboard Cite

Purpose: To describe secondary care health care resource utilization (HCRU) for children and adolescents with atopic dermatitis (AD).Patients and Methods: This UK chart review of patients with moderate-to-severe AD was conducted in four National Health Service hospitals. Cohorts were defined by age (children 6-11 years, adolescents 12-17) at first consultation. Eligible patients were selected consecutively, starting with the most recently consulting patient. At least 12 months' data were abstracted from medical records. Data were collected on HCRU, demographics/clinical characteristics, treatment, and patient-reported outcomes.Results: Data were abstracted for 55 patients. Most patients (80%) had severe AD at first referral, a mean (SD) of 3.2 (10.7) patient-reported flare episodes/patient/yearof-observation, and 18.5 (16.7) tests/scans/procedures/patient/year. Mean (SD) observation duration was 3.6 (1.8) years. Patients had tried mean (SD) 7.9 (5.3) treatments/ patient/year of observation. Topical corticosteroids (TCS; 24.5% of prescriptions) were most frequently prescribed. Mean (SD) use of emollients/moisturizers, TCS, systemic corticosteroids, and systemic immunosuppressants was 30.9 (21.3), 21.1 (23.4), 1.7 (8.3), and 7.8 (8.2) months. There was a mean (SD) of 5.3 (2.9) consultations/patient/year-ofobservation; 116 (10.7%) for flare. Most hospitalizations (87.5%) were for children; the 8/55 (15%) hospitalized patients (mean 2.0 hospitalizations/patient during observation period) spent 6.2 (SD: 5.1) nights in hospital/hospitalization. Earliest mean (SD) Children's Dermatology Life Quality Index score was 15.3 (7.2); latest was 12.9 (7.5). Conclusion:Children and adolescents with moderate-to-severe AD had a high HCRU burden and small changes in quality of life, indicating that current treatments may provide suboptimal AD control in most cases.

show abstract

Section: Introductionmentioning

confidence: 88%

“…10 An equivalent Irish pediatric study supported these findings. 11 The present study aimed to describe secondary care health care resource utilization (HCRU), patient demographics, and patient-reported outcome data for children and adolescents with moderate-to-severe AD in the UK.…”

Section: Introductionmentioning

confidence: 99%